Buy Suprax (Cefixime) Online — Once-Daily Third-Generation Cephalosporin Antibiotic for UTI, Pediatric Otitis Media & Sinusitis

🔑 Core identity in one paragraph

Cefixime belongs to the third-generation cephalosporin class, sharing structural family with ceftriaxone, cefotaxime, and ceftazidime. Unlike those parenteral third-generation agents, cefixime is orally bioavailable, which makes it distinctive: extended Gram-negative coverage in an oral tablet or suspension form. This oral availability drives its clinical role in outpatient treatment of infections that historically required intramuscular or intravenous cephalosporin therapy.

🧪 Why cefixime is distinctive

Most third-generation cephalosporins (ceftriaxone, cefotaxime) are IV/IM only. Cefixime's oral bioavailability was a landmark development, allowing outpatient extended Gram-negative coverage without injection. This positioned it well for community-acquired UTIs, otitis media in children, and step-down therapy after IV cephalosporins. It also became historically important for oral gonorrhoea treatment before resistance eroded that role.

✅ Clinical role today

• Uncomplicated UTI caused by susceptible E. coli, Proteus mirabilis, Klebsiella
• Acute otitis media in children as beta-lactam alternative
• Acute bacterial sinusitis in beta-lactam-allergic patients (non-severe allergy)
• Streptococcal pharyngitis in penicillin allergy (non-severe)
• Typhoid fever uncomplicated cases in endemic regions
• Step-down therapy after IV ceftriaxone for various infections
• Gonorrhoea role has narrowed dramatically; now largely restricted to specific alternative regimens

📅 Development timeline

Early 1980s — molecular design at Fujisawa

Fujisawa chemists develop cefixime as an orally bioavailable third-generation cephalosporin. The chemical structure includes a vinyl group at position 3 and an aminothiazolyl oxyimino side chain characteristic of third-generation cephalosporins.

1987 — Japanese launch

Launched in Japan as Cefspan (Fujisawa). First-in-class oral third-generation cephalosporin.

1989 — FDA approval as Suprax

US approval by Lederle Laboratories. Marketed for respiratory tract infections, UTIs, and gonorrhoea.

1990s — global expansion

Approved across Europe, Asia, Latin America, Middle East. Becomes a routine outpatient antibiotic. Widely adopted in paediatric practice through suspension formulations.

2003 — brief US market withdrawal by Wyeth

Wyeth (which had acquired Lederle) discontinued Suprax marketing in the US for commercial reasons in 2003. This left a treatment gap for oral third-generation cephalosporin therapy.

2004 — relaunch by Lupin

Lupin Pharmaceuticals (India) acquired US marketing rights and relaunched Suprax. This provided renewed access, particularly important for paediatric practice.

2007-2012 — gonorrhoea treatment failures documented

Cases of cefixime treatment failure for N. gonorrhoeae reported first in Japan (Unemo and colleagues), then in Australia, Europe. Rising MICs prompt CDC to remove cefixime as recommended first-line for gonorrhoea in 2012.

2015 to present — ongoing role narrowing

Extended-spectrum beta-lactamase (ESBL) rise in community E. coli reduces cefixime UTI reliability in some regions. Cefixime retains significant role in typhoid fever, paediatric otitis media, and specific outpatient settings. Also remains in select STI regimens as alternative to ceftriaxone.

🇯🇵 The Japanese connection

Fujisawa Pharmaceutical was a major player in cephalosporin chemistry, developing many first- and second-generation cephalosporins alongside cefixime. Japan's aggressive cephalosporin prescribing pattern in the 1990s and 2000s (including widespread outpatient cefixime use) is thought to have contributed to the emergence of cefixime-resistant N. gonorrhoeae in Japan first. This experience became an early warning that shaped global surveillance strategies.

✅ Why cefixime persisted despite gonorrhoea role loss

Even after gonorrhoea treatment failures narrowed its role in STI treatment, cefixime remains valuable for many other indications where its oral third-generation coverage is uniquely useful. Paediatric otitis media, uncomplicated UTI, and typhoid fever — particularly in outpatient and low-resource settings — all continue to use cefixime as a well-established option. Global generic availability keeps it broadly accessible.

🧬 Mechanism step by step

1. Absorption and entry: cefixime crosses Gram-negative outer membrane through porin channels; readily accesses periplasmic space
2. PBP binding: the beta-lactam ring binds specific penicillin-binding proteins (PBPs 1a, 1b, 3 primarily) at the bacterial cytoplasmic membrane
3. Transpeptidase inhibition: bound PBP cannot catalyse the transpeptidation step that cross-links adjacent peptidoglycan strands
4. Cell wall weakening: newly synthesised peptidoglycan is not cross-linked and does not have full mechanical strength
5. Autolysin activation: the imbalance triggers bacterial autolysins that degrade cell wall material further
6. Cell lysis: growing bacteria burst under internal osmotic pressure. Non-growing bacteria escape more slowly but eventually succumb.

🔬 Why the third-generation matters

Third-generation cephalosporins including cefixime were engineered with side chains that: (1) penetrate Gram-negative outer membranes more efficiently than earlier generations; (2) resist most narrow-spectrum beta-lactamases produced by common Enterobacteriaceae; and (3) maintain PBP binding in a range of pathogens. The trade-off is reduced Gram-positive activity compared with first- and second-generation cephalosporins.

✅ Post-antibiotic effect

Cefixime demonstrates a modest post-antibiotic effect against susceptible Gram-negatives, meaning bacterial regrowth is briefly suppressed after drug concentrations fall below the MIC. This supports the practical efficacy of once-daily dosing despite time-dependent killing being the primary pharmacodynamic characteristic. For most indications, 400 mg once daily maintains adequate time above MIC.

🔑 Where cefixime fits within third-generation cephalosporins

Oral bioavailability

Cefixime is one of few third-generation cephalosporins available as oral tablets or suspension. Others in this oral third-generation subgroup: cefpodoxime proxetil, cefdinir, cefditoren pivoxil, ceftibuten.

Coverage comparison

Similar Gram-negative spectrum to IV ceftriaxone but less potent overall. Reduced Gram-positive activity relative to ceftriaxone. No pseudomonal coverage (unlike ceftazidime).

Half-life advantage

3 to 4 hours plasma half-life; adequate for once-daily or BID dosing for most indications. Ceftriaxone's much longer half-life (7 to 8 hours) allows once-daily IV/IM dosing.

Clinical role

Bridges outpatient practice with cephalosporin-level Gram-negative coverage. Historically used for gonorrhoea until resistance emerged.

🔬 Third-generation strengths

• Extended Gram-negative coverage (Enterobacteriaceae, Haemophilus, Neisseria)
• Resistance to many narrow-spectrum beta-lactamases
• Improved CNS penetration (relevant to IV ceftriaxone for meningitis; less relevant to cefixime)
• Convenient once-daily dosing (cefixime and ceftriaxone)
• Well-tolerated in most patients

⚠️ Third-generation weaknesses

Third-generation cephalosporins including cefixime have historically been strongly associated with C. difficile infection. They select for ESBL-producing Enterobacteriaceae and are among the antibiotic classes most implicated in this resistance mechanism's emergence. In antimicrobial stewardship programmes, third-generation cephalosporin use is a focus for reduction where narrower agents suffice.

✅ Reliable coverage

• Haemophilus influenzae (beta-lactamase producing and non-producing)
• Moraxella catarrhalis
• E. coli (non-ESBL-producing)
• Klebsiella pneumoniae (non-ESBL-producing)
• Proteus mirabilis
• Neisseria meningitidis
• Streptococcus pyogenes (Group A strep)
• Streptococcus pneumoniae (susceptible strains, regional variability)
• Salmonella enterica serovar Typhi (traditional strains)
• Shigella species (many)

🟡 Variable or reduced coverage

• Streptococcus pneumoniae with reduced penicillin susceptibility — regional variability
• Neisseria gonorrhoeae — rising MICs; treatment failures documented; no longer first-line
• ESBL-producing Enterobacteriaceae — resistant
• AmpC-producing organisms (some Enterobacter, Citrobacter) — variable
• Multidrug-resistant Salmonella Typhi (XDR strains in Pakistan and elsewhere) — resistant

🔴 Gaps: do not use for these

• Staphylococcus aureus (MSSA or MRSA) — limited activity even against MSSA; use cefazolin or cephalexin instead for MSSA
• Enterococcus (E. faecalis, E. faecium) — intrinsically resistant
• Pseudomonas aeruginosa — no activity
• Acinetobacter baumannii — no activity
• Anaerobes below the diaphragm (Bacteroides fragilis group) — limited activity
• Listeria monocytogenes — intrinsically resistant (avoid in listerial infection)
• Atypical respiratory pathogens (Mycoplasma, Chlamydia, Legionella) — no beta-lactam covers these
• Mycobacteria — not effective

🧪 Practical spectrum takeaway

Cefixime is best thought of as a good Gram-negative outpatient oral option particularly for community E. coli, Haemophilus, Moraxella, and Salmonella Typhi. It is not a good choice for staphylococcal or enterococcal infections (use different classes), for Pseudomonas (use antipseudomonal agents), or for typical CAP where atypical coverage matters (macrolide or doxycycline better as monotherapy). ESBL and XDR concerns in local populations increasingly limit its Gram-negative empirical role.

🔬 What tissue distribution means clinically

Cefixime achieves adequate concentrations in urine, respiratory secretions, middle ear fluid, sinus mucosa, and bile. This supports its efficacy for UTI, respiratory tract infections, and otitis media. It does NOT penetrate CSF adequately, so cefixime is not appropriate for meningitis or other CNS infections — IV ceftriaxone or cefotaxime would be needed for those indications.

🕑 Practical dosing implications

• Once daily or twice daily both acceptable; 400 mg OD or 200 mg BID equivalent for most indications
• Take with or without food — convenience advantage
• Full course completion important given time-dependent killing
• Renal dose adjustment at CrCl below 60 mL/min (see dedicated section)
• Not for meningitis or CNS infection — use IV third-generation cephalosporin
• High urinary concentrations make cefixime a natural choice for cystitis and pyelonephritis where organism is susceptible

✅ Convenience advantage

Cefixime's once-daily dosing plus lack of strict food or timing rules make it one of the more convenient oral antibiotics available. This translates to good real-world adherence for outpatient courses. For a 7 to 14 day treatment for uncomplicated UTI, otitis media, or sinusitis, the practical burden on the patient is minimal compared with QID tetracyclines or TID amoxicillin regimens.

🚽 UTI treatment framework

Uncomplicated cystitis first-line options

Nitrofurantoin 100 mg BID for 5 days OR trimethoprim-sulfamethoxazole 160/800 mg BID for 3 days (if local resistance under 20 percent) OR fosfomycin 3 g single dose OR cefixime 400 mg daily for 7 days.

Cefixime specific role

Reasonable alternative when first-line agents are contraindicated or when a broader spectrum for potential upper tract involvement is desired. Once-daily dosing convenience.

Uncomplicated pyelonephritis (outpatient)

Fluoroquinolone (ciprofloxacin, levofloxacin) or trimethoprim-sulfamethoxazole where resistance permits. Cefixime as alternative in beta-lactam-appropriate cases; sometimes IV ceftriaxone loading dose then oral cefixime step-down.

Complicated UTI

IV therapy often needed; cefixime may serve as step-down oral after IV response.

Male UTI

Considered complicated; cefixime acceptable for 7 to 14 days depending on prostate involvement suspicion.

Recurrent UTI

Different approach; not typically cefixime; consider nitrofurantoin or trimethoprim prophylaxis.

⚠️ ESBL resistance limits empirical use

Extended-spectrum beta-lactamase (ESBL) producing E. coli have spread substantially in community populations globally. In regions with community ESBL rates over 15 to 20 percent, empirical cefixime for UTI risks treatment failure. Local surveillance data should guide empirical choice. For patients with prior ESBL infection, recent hospitalisation, or foreign travel, cefixime may not be adequate and culture-directed therapy or broader coverage is preferred.

🧪 When cefixime is the right UTI choice

Uncomplicated cystitis in low-ESBL communities; pregnancy (Category B; safer than fluoroquinolones); paediatric UTI; step-down after IV ceftriaxone for pyelonephritis; when first-line agents (nitrofurantoin, trimethoprim-sulfamethoxazole) are contraindicated or intolerable. Cefixime BID 200 mg is also sometimes used for cystitis in patients with sensitive stomach as it may be better tolerated than 400 mg OD.

👂 AOM treatment framework

First-line: amoxicillin high-dose

Amoxicillin 80 to 90 mg/kg/day divided BID or TID for 10 days in children under 2; shorter courses (5 to 7 days) in older children with mild disease. Pneumococcal and streptococcal coverage.

Second-line: amoxicillin-clavulanate

Same amoxicillin dose plus clavulanate. For treatment failure or severe presentation. Better coverage of beta-lactamase-producing H. influenzae and M. catarrhalis.

Cefixime alternative

Cefixime 8 mg/kg once daily for 10 days. Alternative for beta-lactam-tolerating patients where amoxicillin regimen has failed, in penicillin-allergic children (non-severe allergy), or where adherence with once-daily is beneficial.

Cefixime advantages in AOM

Excellent H. influenzae coverage including beta-lactamase producers. Once-daily convenience. Palatable suspension formulations. Age approved from 6 months.

Cefixime limitations in AOM

Limited pneumococcal activity compared with high-dose amoxicillin; therefore not first-line where pneumococcus dominates.

🔑 When cefixime fits AOM well

• H. influenzae-dominant AOM (fever, purulent otorrhoea, older children)
• Amoxicillin high-dose treatment failure at 48 to 72 hours
• Penicillin allergy (non-severe, non-anaphylactic)
• Adherence concerns favouring once-daily dosing
• Recurrent AOM despite amoxicillin courses

⚠️ When cefixime is not the best AOM choice

Regions with high pneumococcal resistance to cephalosporins; severe AOM presentations; children under 6 months (not FDA approved); anaphylactic penicillin allergy (avoid all beta-lactams). For most first-episode uncomplicated AOM without penicillin allergy, high-dose amoxicillin remains first-line. Cefixime step-up or alternative role fits specific situations.

👇 Acute bacterial sinusitis treatment framework

First-line: amoxicillin-clavulanate

High-dose amoxicillin 875 mg BID plus clavulanate for 5 to 10 days. Covers pneumococcus plus beta-lactamase-producing H. influenzae and Moraxella.

Cefixime as alternative

Cefixime 400 mg once daily or 200 mg BID for 5 to 10 days. Options for beta-lactam-appropriate patients with amoxicillin-clavulanate intolerance or as step-up therapy after amoxicillin monotherapy failure.

Doxycycline alternative

Doxycycline 100 mg BID for 5 to 10 days. Reasonable in penicillin allergy or where cephalosporins are declined.

Fluoroquinolone reserved

Levofloxacin or moxifloxacin reserved for treatment failure or specific clinical situations due to FDA black box warnings.

🧪 Distinguishing viral from bacterial sinusitis matters

Most sinus symptoms are viral. Antibiotic treatment is not indicated for viral sinusitis. Bacterial sinusitis is suggested by: symptoms persisting more than 10 days without improvement; severe symptoms with high fever and purulent discharge lasting 3 to 4 days; symptoms that improved then worsened (double sickening). Only when bacterial sinusitis is suspected does cefixime or any antibiotic become an appropriate choice.

✅ Cefixime advantages in sinusitis

Once-daily dosing supports adherence over a 5 to 10 day course. Good tolerability with modest GI upset only. Adequate coverage of the two most common bacterial pathogens (H. influenzae and M. catarrhalis, both often beta-lactamase producing). Pregnancy-acceptable. Available in oral suspension for paediatric use.

🗣️ Streptococcal pharyngitis treatment framework

First-line: penicillin V or amoxicillin

Penicillin V 500 mg BID for 10 days OR amoxicillin 500 mg BID or 1000 mg once daily for 10 days. Full 10-day course required for strep eradication and rheumatic fever prevention.

Cefixime alternative (non-severe penicillin allergy)

Cefixime 400 mg once daily for 10 days. Acceptable in non-severe penicillin allergy (rash but not anaphylaxis). Streptococcus pyogenes remains uniformly cefixime-susceptible.

Severe penicillin allergy (anaphylaxis)

Avoid cephalosporins including cefixime. Use clindamycin, macrolide (azithromycin, clarithromycin), or clindamycin.

Cefixime advantages here

Once-daily dosing (adherence advantage); no macrolide resistance issue (relevant in high-macrolide-resistance regions); pregnancy Category B; safe in children with suspension.

⚠️ Complete 10 days regardless of symptom resolution

Full 10-day antibiotic course is required for streptococcal eradication and prevention of post-streptococcal complications (rheumatic fever, acute glomerulonephritis). Stopping cefixime early after symptom improvement risks these serious sequelae. Some newer studies suggest shorter courses may work in specific settings but 10 days remains standard of care.

🧪 Testing before treatment

Most sore throats are viral. Rapid antigen detection tests (RADT) or throat culture confirm streptococcal aetiology before antibiotic prescription. Empirical antibiotic treatment for undifferentiated sore throat is not appropriate. Cefixime for pharyngitis should be reserved for confirmed streptococcal infection meeting the criteria above, not for empirical viral URI treatment.

🔴 Current CDC (2021) and WHO gonorrhoea framework

First-line uncomplicated gonorrhoea: ceftriaxone 500 mg IM single dose (higher dose than previously; increased from 250 mg due to resistance concerns). Doxycycline 100 mg BID for 7 days is added if chlamydia has not been excluded. Cefixime is no longer recommended as first-line for uncomplicated gonorrhoea.

💉 Historical timeline of cefixime in gonorrhoea

1989 to 2007 — cefixime 400 mg single dose was first-line

Convenient oral single-dose option for uncomplicated gonorrhoea. Highly effective; nearly 100 percent cure rates in early years.

2007 to 2010 — treatment failures documented in Japan

Unemo and colleagues report cefixime treatment failures for pharyngeal gonorrhoea. MICs to cefixime rising. Molecular characterisation of the F89 clone.

2010 to 2012 — similar reports from Europe, Australia

Rising MICs and treatment failures across multiple settings. CDC and WHO note growing concern.

2012 — CDC removes cefixime as first-line

CDC removes cefixime 400 mg from first-line for gonorrhoea. Ceftriaxone 250 mg IM plus azithromycin 1 g becomes dual therapy recommendation.

2015 to 2021 — further evolution

Ceftriaxone dose increased to 500 mg IM. Azithromycin dual therapy dropped in some newer CDC guidance due to azithromycin resistance concerns. Cefixime retained as narrow alternative only when ceftriaxone truly unavailable.

Present — cefixime remains a very limited option

In settings without ceftriaxone availability, cefixime 800 mg oral (higher than historical 400 mg) plus azithromycin has been considered. Not preferred; not first-line.

⚠️ If cefixime must be used for gonorrhoea

• Only when ceftriaxone is truly not accessible
• Higher-dose (800 mg oral) is preferred over historical 400 mg
• Consider adding azithromycin 1 g single dose
• Confirm test of cure at 7 to 14 days (especially for pharyngeal)
• Culture and susceptibility testing before treatment where possible
• Report treatment to public health surveillance
• Contact tracing and partner treatment essential

🧪 Why gonorrhoea resistance evolves so rapidly

N. gonorrhoeae is naturally competent for transformation, readily incorporating resistance-encoding DNA from other bacteria. Once a resistance mechanism emerges anywhere, it can spread quickly through global sexual networks. Cefixime resistance emerged from mosaic penA gene alterations that also convey partial ceftriaxone resistance. This is why gonorrhoea treatment framework updates rapidly and why parallel drug development is a global priority.

✅ Practical clinical framework

If you are treating suspected or confirmed gonorrhoea in most settings, use ceftriaxone 500 mg IM (not cefixime). Cefixime should not be considered a substitute for the injectable option unless there is a very specific reason (documented allergy to injectable formulations, no IM access, resource limitations) and even then, expert consultation and follow-up testing are essential.

🌡️ Typhoid treatment framework

Uncomplicated typhoid, susceptible strain

Cefixime 20 mg/kg/day (max 400 mg BID) for 7 to 14 days OR ciprofloxacin 500 mg BID for 7 to 14 days OR azithromycin 500 mg to 1 g daily for 7 to 14 days.

Multidrug-resistant typhoid (MDR)

Resistant to older agents (chloramphenicol, cotrimoxazole, ampicillin) but susceptible to fluoroquinolones and cephalosporins. Cefixime 20 mg/kg/day BID for 14 days is a standard oral option.

Fluoroquinolone non-susceptible strains

Rising in South Asia. Cefixime 20 mg/kg/day for 14 days OR azithromycin 500 mg to 1 g daily.

Extensively drug-resistant (XDR) typhoid

Emerging particularly in Pakistan (H58 lineage). Resistant to first-line, fluoroquinolones, AND third-generation cephalosporins including cefixime. Azithromycin and carbapenems remain effective. Regional surveillance essential.

Severe or complicated typhoid

Hospitalisation, IV therapy needed. Ceftriaxone or azithromycin IV/PO. Cefixime not appropriate as monotherapy for severe disease.

🔴 XDR typhoid emerging concern

Since 2016, XDR typhoid H58 lineage has spread from Sindh, Pakistan across South Asia. XDR strains are resistant to chloramphenicol, ampicillin, cotrimoxazole, fluoroquinolones, AND third-generation cephalosporins (including cefixime and ceftriaxone). Treatment requires azithromycin or carbapenems. This has major implications for regions with XDR spread — cefixime is not adequate empirical therapy where XDR is prevalent. Regional surveillance and travel history matter.

🧪 Response monitoring

Typhoid response is slower than most bacterial infections. Fever may persist for 4 to 7 days after starting effective therapy. Failure to defervesce by day 5 to 7 warrants reassessment of susceptibility and consideration of alternative therapy. Blood cultures ideally guide susceptibility. Repeat cultures at day 5 to 7 in poor responders help detect resistance.

✅ Public health context

Typhoid prevention through water, sanitation, and hygiene remains foundational. Typhoid conjugate vaccine (TCV) programmes are expanding in endemic settings (Pakistan, Malawi, others). Cefixime and other treatment options work best when combined with public health prevention. Individual cefixime treatment does not address the underlying disease burden; vaccination and infrastructure investments do.

💊 Once daily versus twice daily — which to pick

Both regimens deliver the same total daily dose. Choice depends on practical factors:

• Once daily 400 mg: simpler adherence, single-alarm dosing, most patient preference
• Twice daily 200 mg: may be marginally better tolerated in patients prone to nausea; smoother steady-state; some prefer for typhoid where 400 mg BID at total 800 mg/day is used
• For serious infections (pyelonephritis, typhoid): BID often preferred for more consistent tissue levels
• For uncomplicated cystitis or sinusitis: once daily works fine

🕑 Practical administration tips

• Take with or without food — convenience advantage
• Full glass of water for standard swallowing
• Chewable formulation should be chewed thoroughly before swallowing
• Space BID doses approximately 12 hours apart
• Complete the full course even if symptoms resolve early
• Do not double doses if one is missed — see missed dose section
• For typhoid: 400 mg BID rather than 400 mg OD provides more reliable levels for this serious systemic infection

✅ Why the standard dose is 400 mg

The 400 mg total daily dose reflects the pharmacokinetic-pharmacodynamic properties of cefixime. Peak concentrations at this dose reliably exceed MICs for target organisms in urinary, respiratory, and soft tissue compartments. Higher doses (800 mg) are sometimes considered for gonorrhoea to overcome rising MICs, and for typhoid where 400 mg BID provides sustained tissue levels. Lower doses risk sub-therapeutic exposure and treatment failure.

👶 Paediatric formulations

Oral suspension (100 mg per 5 mL, 200 mg per 5 mL)

Reconstituted with water. Strawberry flavour common in Suprax; palatability generally good. Refrigerate after reconstitution; use within 14 days.

Chewable tablets

Multiple strengths available. Chew thoroughly before swallowing. Palatable flavours. Convenient alternative to suspension.

Tablets (200 mg, 400 mg)

For children able to swallow tablets, typically age 8+ years.

✅ Paediatric practical tips

• Shake suspension well before each dose
• Measure with the provided dosing device (syringe or measuring cup) — NOT household teaspoons
• Refrigeration of suspension enhances taste palatability
• Give with or without food; food may improve tolerability
• Complete the full course — explain to parents that symptom improvement does not mean infection is cleared
• Watch for diarrhoea (common); severe diarrhoea warrants evaluation for CDI
• Report rash promptly (rare severe skin reactions possible)

🧪 Weight-based dosing worked examples

For a 15 kg child (approximately 3 years): 15 kg × 8 mg/kg = 120 mg/day. Round to nearest measurable dose: 100 mg suspension once daily, or 60 mg BID. For a 30 kg child (approximately 10 years): 30 kg × 8 mg/kg = 240 mg/day. Give 200 mg suspension once daily or 100 mg BID. For typhoid, use 20 mg/kg/day: 15 kg child = 300 mg/day (150 mg BID); 30 kg child = 600 mg/day (300 mg BID, near the adult 400 mg BID dose).

⚠️ When paediatric cefixime is NOT the right choice

Age under 6 months (not FDA approved); severe or complicated infection requiring IV therapy; suspected pneumococcal-dominant AOM where high-dose amoxicillin better; anaphylactic penicillin allergy (avoid all beta-lactams); prior severe cefixime reaction. For most first-episode uncomplicated paediatric AOM in low-macrolide-resistance regions, high-dose amoxicillin remains first-line.

🧪 Why kidney disease affects cefixime

Cefixime is eliminated approximately 50 percent unchanged in urine, plus additional biliary excretion. In CKD, unchanged drug accumulates because glomerular filtration and tubular secretion are reduced. Standard dosing at CrCl below 60 mL/min can produce plasma levels above the therapeutic range, increasing adverse effect risk without additional efficacy benefit. Simple dose reduction addresses this.

✅ Practical prescribing in CKD

• Check recent creatinine and eGFR before prescribing
• Use 300 mg dose if CrCl 21 to 60 mL/min
• Use 200 mg dose if CrCl under 20 mL/min or on dialysis
• Time dose after dialysis session to avoid removing much of the dose
• Watch for GI adverse effects which may be more prominent with accumulation
• Watch for C. difficile which older CKD patients are more susceptible to
• Do not adjust further based on age alone if renal function is normal

🧪 Hepatic elimination is minor

Unlike tetracycline HCl (predominantly renal + biliary), macrolides (hepatic), and metronidazole (hepatic), cefixime is not extensively hepatically metabolised. This means liver disease alone rarely requires dose adjustment. However, combined kidney and liver disease can compound and reduce clearance more than either alone; monitor and consider dose modification if accumulation is suspected.

🔑 Warfarin interaction in practice

Cefixime, like most broad-spectrum antibiotics, can potentiate warfarin's anticoagulant effect. The mechanism is reduction of vitamin K-producing gut flora. INR elevation of 0.5 to 1.5 points during a course is not unusual. Check INR at 3 to 5 days after starting, and anticipate modest reduction in warfarin dose or more frequent monitoring. This is a class effect for many antibiotics; cefixime is not the worst offender but the interaction is real.

🧪 Probenecid interaction is sometimes intentional

Probenecid blocks renal tubular secretion of cefixime, roughly doubling plasma levels. This can be used deliberately in specific clinical situations to boost cefixime exposure — particularly historical gonorrhoea treatment and some cases of pyelonephritis. In modern practice this is uncommon; ceftriaxone IM or oral cefixime higher dose usually suffices. If probenecid is coincidentally on the medication list, cefixime dose reduction is generally not needed for short courses but monitoring is prudent.

✅ Clean interaction profile advantages

• No CYP3A4 concerns unlike clarithromycin, erythromycin
• No chelation issues unlike tetracyclines
• No QT prolongation concern unlike macrolides or fluoroquinolones
• No significant food restrictions
• Safe with common medications: statins, digoxin, most seizure medications, antihypertensives
• This clean profile makes cefixime a reasonable choice for polypharmacy patients when the indication fits

⚠️ One notable caution

If a patient is scheduled to receive live oral typhoid vaccine (Ty21a) for travel prophylaxis, cefixime taken within 72 hours can inactivate the vaccine bacteria. Space cefixime and vaccine by at least 3 days. This does not apply to injectable typhoid Vi vaccine, which is not affected by antibiotics.

✅ Pregnancy safety considerations

Animal reproductive studies

No teratogenic effects observed at doses several-fold higher than human therapeutic doses.

Human pregnancy data

Registry data and epidemiological studies show no clear signal for increased birth defects. Cefixime shares the good pregnancy safety profile of the cephalosporin class as a whole.

Placental transfer

Cefixime crosses the placenta but concentrations in fetal circulation are modest.

FDA Category B

Cefixime is Category B (previously; older FDA categories still commonly cited). Adequate and well-controlled human studies not required to establish absence of risk given class experience.

🍼 Lactation

Small amounts of cefixime transfer into breast milk (milk-to-plasma ratio approximately 0.1). Estimated infant dose is well below therapeutic levels. Cefixime is generally considered compatible with breastfeeding. Watch the breastfed infant for signs of diarrhoea, oral thrush, or rash; discontinuation of maternal treatment for these is rarely necessary.

🧪 Why cephalosporins are relatively pregnancy-safe

Beta-lactams including cephalosporins have decades of pregnancy use with reassuring safety data. Unlike tetracyclines (Category D, tooth staining, hepatotoxicity), fluoroquinolones (Category C, cartilage concerns), or sulfonamides (kernicterus concern in late pregnancy), cephalosporins have no established teratogenic risk. This makes them frequently prescribed during pregnancy when a beta-lactam antibiotic is appropriate.

✅ Pre-pregnancy and post-partum

Women of childbearing potential do not need special counselling about cefixime beyond the standard antibiotic consultation. If a patient becomes pregnant during a cefixime course, the exposure history is reassuring and continuation is typically appropriate to complete the necessary treatment. No special congenital anomaly screening is warranted.

✅ Practical management

• Diarrhoea: usually mild and self-limiting; if watery/frequent/bloody, evaluate for CDI (see dedicated section)
• Nausea: taking with a small snack helps without significantly affecting absorption; BID 200 mg often better tolerated than OD 400 mg for GI-sensitive patients
• Adequate hydration helps overall tolerability
• Mild rash: consider antihistamine; discontinue if progressive or systemic features
• Candidiasis: symptomatic treatment (topical antifungal); probiotic yoghurt separately timed may help
• Complete the course despite mild side effects when possible

⚠️ Cefixime diarrhoea is more common than average

Cefixime, like other third-generation cephalosporins, has a higher rate of dose-related diarrhoea than first-generation cephalosporins (cephalexin) or amoxicillin. The reason is broader Gram-negative activity that disrupts more of the gut flora. In some patient populations (particularly children), diarrhoea from cefixime can lead to interrupted courses. Counsel parents and patients that mild diarrhoea is expected but severe diarrhoea warrants medical review.

🧪 When to stop treatment

Most mild side effects allow completion of the course. Reasons to discontinue and reassess: progressive rash suggesting allergic reaction; severe watery or bloody diarrhoea suggesting CDI; jaundice or right upper quadrant pain; signs of hypersensitivity reaction; oesophageal symptoms of blistering skin reactions. Contact the prescriber — do not simply switch antibiotics without medical review.

✅ When cefixime is preferred among oral cephalosporins

• Uncomplicated UTI with E. coli or Klebsiella (non-ESBL)
• Otitis media or sinusitis where H. influenzae or Moraxella predominate
• Typhoid fever (specific approved indication)
• Streptococcal pharyngitis penicillin allergy where once-daily preferred
• Once-daily convenience is a priority

🔑 When other cephalosporins are preferred

• Cephalexin (1st gen): staph or strep skin/soft tissue infection; cellulitis without atypical concern
• Cefuroxime (2nd gen): balanced coverage where both Gram-positive and Gram-negative matters (Lyme disease, some sinusitis)
• Cefpodoxime (3rd gen): similar spectrum to cefixime but with slightly better pneumococcal activity in some settings
• Cefdinir (3rd gen): paediatric preferred by some for AOM due to palatable suspension

✅ When amoxicillin-clavulanate is preferred

• Sinusitis or otitis media where pneumococcus needs full coverage
• Bite wounds requiring anaerobic and Staph coverage
• Dental infections
• Skin infections including cellulitis
• Aspiration pneumonia (mixed flora)
• Cost sensitivity in setting where both work

🔑 When cefixime is preferred over amoxicillin-clavulanate

• Non-severe penicillin allergy history
• Amoxicillin-clavulanate intolerance (diarrhoea, GI upset)
• Uncomplicated UTI where cephalosporin adequate
• Typhoid fever
• Once-daily dosing preferred over BID/TID for adherence
• Extended H. influenzae coverage in specific pulmonary infections

🧪 Clavulanate GI effect

Amoxicillin-clavulanate causes more diarrhoea than plain amoxicillin due to the clavulanate component's prokinetic effect on the intestines. In patients previously intolerant of amoxicillin-clavulanate for this reason, cefixime is a reasonable alternative when a beta-lactam is still appropriate. The extended H. influenzae coverage is comparable, and pneumococcal coverage is somewhat reduced — a trade-off worth considering based on suspected pathogen.

✅ When cefixime is preferred over fluoroquinolones

• Pregnancy (Category B vs contraindicated)
• Children (approved from 6 months vs not typically used)
• Prior fluoroquinolone adverse reaction (tendinitis, dysglycaemia, neuropathy)
• Concurrent QT-prolonging medications
• History of aortic aneurysm or connective tissue disease
• Uncomplicated UTI where either would work
• Elderly patients with polypharmacy

🔑 When fluoroquinolones are preferred

• Complicated UTI requiring broader Gram-negative coverage including Pseudomonas
• Community-acquired pneumonia requiring monotherapy with pneumococcus + atypical coverage
• Prostatitis (better prostate tissue penetration)
• Legionella pneumonia (severe)
• Anthrax or plague empirical bioterrorism prophylaxis

🔴 FDA fluoroquinolone black box warnings

The FDA in 2016 and subsequent years added black box warnings to systemic fluoroquinolones covering: tendinitis and tendon rupture; peripheral neuropathy; CNS effects; aortic aneurysm/dissection risk; blood glucose disturbances. FDA recommends reserving fluoroquinolones for indications where alternatives are unsuitable. For uncomplicated cystitis specifically, FDA states fluoroquinolones should NOT be used as first-line when alternatives are available. This regulatory context has shifted uncomplicated UTI treatment back toward cefixime, nitrofurantoin, and trimethoprim-sulfamethoxazole.

🔴 Severe adverse effects to recognise

Severe hypersensitivity reactions

Anaphylaxis (rare but possible, especially in true penicillin-allergic patients); angioedema (rare); Stevens-Johnson syndrome / toxic epidermal necrolysis (very rare); DRESS syndrome (very rare). Any severe skin reaction requires immediate discontinuation.

Clostridioides difficile-associated diarrhoea (CDI)

Third-generation cephalosporins have historically been strongly associated with CDI. Severe watery or bloody diarrhoea during or after therapy warrants urgent evaluation. See dedicated section.

Pseudomembranous colitis

Severe C. difficile colitis. Persistent severe diarrhoea after treatment ends requires urgent evaluation.

Hepatotoxicity

Rare. Cholestatic hepatitis, transient LFT elevation, rare cases of hepatic failure. See dedicated section.

Renal effects

Rare interstitial nephritis (hypersensitivity mediated); dose-related accumulation in CKD if not adjusted.

Haematologic effects

Rare thrombocytopenia, neutropenia, haemolytic anaemia; rare Coombs-positive test. See dedicated section.

Seizures

Very rare with cefixime at usual doses; higher risk with impaired renal function and accumulation.

Serum sickness-like reaction

Fever, arthralgia, rash 1 to 3 weeks after starting. More common in children than adults for the cephalosporin class.

Vitamin K deficiency and bleeding

Rare from gut flora disruption; more common in malnourished or long-course patients.

⚠️ Warning signs requiring immediate medical attention

• Difficulty breathing, throat tightness, or wheezing
• Rapid swelling of face, lips, or tongue
• Widespread rash with blistering, mucosal involvement, or peeling skin
• Severe watery or bloody diarrhoea (during or after treatment)
• Yellow skin or eyes, dark urine, or right upper quadrant pain
• Reduced or absent urine output
• Unusual bleeding or bruising
• Fever, chills, sore throat during treatment
• Severe joint pain, rash, and fever 1 to 3 weeks after starting
• Confusion, altered consciousness, or seizure

🔑 Higher-risk patient groups for severe adverse effects

• Prior severe reaction to any cephalosporin or penicillin
• Prior CDI or ongoing high antibiotic exposure
• Older adults (higher CDI risk generally)
• Renal impairment (accumulation without adjustment)
• Immunocompromised patients
• Prolonged courses or repeat courses
• Very young infants
• Malnourished patients (vitamin K and hepatic concerns)
• Concurrent nephrotoxic medications

✅ Overall risk perspective

The vast majority of cefixime courses complete uneventfully with only mild GI symptoms as issues. Serious adverse effects listed here are important to know but statistically uncommon in appropriately selected patients. Recognition speed matters: identifying an evolving allergic reaction, severe diarrhoea suggesting CDI, or hepatic dysfunction early converts a potentially serious event into a manageable one. When in doubt, contact the prescriber rather than continuing through worsening symptoms.

🧪 The old teaching versus current understanding

Old teaching (widely repeated)

"10 percent of penicillin-allergic patients react to cephalosporins." This figure came from small early studies using contaminated first-generation cephalosporins containing trace penicillin.

Modern understanding

True cross-reactivity is approximately 1 to 2 percent for first-generation cephalosporins with penicillin allergy, and under 1 percent for second- and third-generation cephalosporins including cefixime.

Why side chains matter more than the ring

The IgE-mediated allergy response typically targets specific side chains, not the shared beta-lactam ring. First-generation cephalosporins share more side chains with penicillins (cephalexin shares the R1 side chain with amoxicillin). Third-generation cephalosporins including cefixime have very different side chains and rarely trigger cross-reactivity.

✅ Practical framework for cephalosporin use in penicillin-allergic patients

• Documented penicillin allergy without anaphylaxis: cefixime (and other 2nd/3rd gen cephalosporins) are usually acceptable
• Documented penicillin allergy with anaphylaxis or severe cutaneous reaction: avoid all beta-lactams including cephalosporins
• Vague "penicillin allergy" history without documented reaction: consider allergy testing; the vast majority are not truly allergic
• Prior cephalosporin allergy: avoid the same cephalosporin; other cephalosporins with different side chains may be acceptable with specialist input
• Prior aminopenicillin (amoxicillin) allergy: avoid cephalexin and other cephalosporins sharing R1 side chain; cefixime is generally acceptable

🔬 Why the "10 percent" myth persists

The old 10 percent figure appeared in textbooks and medical training for decades and still influences prescribing. In fact, many patients labelled "penicillin-allergic" do not have true IgE-mediated allergy (childhood viral rash, medication side effects mislabelled as allergy, etc). Allergy delabelling programs at major hospitals have shown that up to 90 percent of "penicillin-allergic" patients can safely tolerate penicillins with proper evaluation. For cefixime specifically, the actual cross-reactivity risk in patients with documented penicillin allergy without anaphylaxis is very low.

🔴 The one clear exception

Prior anaphylaxis to penicillin or any beta-lactam should be treated as a lifetime avoidance for the entire beta-lactam class including cefixime, until formal allergist evaluation. Anaphylaxis has a 5 to 10 percent recurrence risk with class rechallenge in some studies. This is a specific clinical situation where the old "avoid all beta-lactams" rule remains sound.

🔴 Allergic reaction spectrum

Mild rash

Diffuse maculopapular or urticarial. Usually appears within days of starting. May be non-allergic (e.g., serum sickness-like); careful history and examination distinguish.

Urticaria (hives)

Raised itchy welts. Discontinue and evaluate.

Angioedema

Swelling of face, lips, tongue. Emergency care; lifetime cephalosporin class avoidance for severe reactions.

Anaphylaxis

Rare with cefixime. Rapid hives, wheezing, throat swelling, hypotension. Emergency care; lifetime beta-lactam class avoidance.

Stevens-Johnson syndrome / TEN

Very rare. Widespread rash with skin peeling and mucosal involvement. Emergency burn-centre care; lifetime avoidance.

DRESS syndrome

Very rare. Widespread rash with fever, facial swelling, eosinophilia, organ involvement. Delayed onset (2 to 8 weeks).

Serum sickness-like reaction

More common in children with cephalosporins than most other antibiotics. Fever, arthralgia, urticarial rash 1 to 3 weeks after starting. Usually resolves with discontinuation.

Acute interstitial nephritis

Hypersensitivity-mediated kidney injury with fever, rash, eosinophilia. Rare but characteristic beta-lactam presentation.

🔑 Cross-reactivity within cephalosporin class

A confirmed severe allergic reaction to any one cephalosporin does not necessarily mean allergy to all cephalosporins. Reactions are typically side-chain specific. A reaction to cefixime does not automatically preclude use of cefazolin, ceftriaxone, or others with different side chains. However for severe reactions (anaphylaxis, SJS/TEN, DRESS), class avoidance is the safer approach until formal allergist evaluation clarifies specific triggers.

🧪 Distinguishing types of rash

Not all rashes during antibiotic therapy are allergic. Common non-allergic possibilities include: viral exanthem coincidental with treatment; drug-induced (non-immunologic) skin reaction; serum sickness-like reaction (more common in children); erythema multiforme; primary skin infection. Careful history (timing, associated symptoms, systemic features) and examination help distinguish. When in doubt, treat as potential allergy for that antibiotic and consider specialist evaluation.

✅ Documentation matters

A confirmed severe cefixime reaction should be documented in the patient's medical record with the specific reaction type and timing. Distinguishing rash from urticaria from angioedema from anaphylaxis matters for future clinical decisions. Vague "cefixime allergy" labels without detail restrict future antibiotic choices unnecessarily. If possible, refer for allergy evaluation and delabelling if the initial reaction description does not fit true IgE-mediated allergy.

🔴 Third-generation cephalosporins are among the highest CDI-risk antibiotics

Historical CDI surveillance identifies clindamycin, fluoroquinolones, and broad-spectrum cephalosporins (particularly third-generation) as the highest-risk antibiotic classes. Amoxicillin, tetracyclines, and macrolides carry lower risk. This risk profile influences empirical prescribing decisions, particularly in older adults, immunocompromised patients, and those with prior CDI.

🧫 CDI mechanism explained

Cefixime's broad Gram-negative activity disrupts gut anaerobes and commensal bacteria that normally suppress C. difficile spore germination and outgrowth. When these bacteria are depleted, C. difficile can proliferate, produce toxins A and B, and cause colitis. Risk increases with prolonged courses, older age, hospitalisation, and concurrent proton pump inhibitors.

🔴 CDI warning signs during or after cefixime

• Frequent watery diarrhoea (over 3 times daily)
• Bloody or mucous stools
• Abdominal cramping, tenderness, or distention
• Fever
• Symptoms persisting after antibiotic course completed
• Diarrhoea developing 1 to 8 weeks after antibiotic exposure (delayed CDI is common)
• New leukocytosis in this context
• Acute kidney injury (particularly in severe CDI)

✅ Reducing CDI risk with cefixime

• Use only when clearly indicated for a bacterial infection
• Complete the appropriate course length (over-treatment increases risk)
• Consider narrower-spectrum alternatives when they cover the target pathogen (nitrofurantoin for UTI; amoxicillin for strep)
• Avoid concurrent unnecessary antibiotics
• Review indication for concurrent PPI (they modestly increase CDI risk)
• Encourage adequate hydration during and after the course
• Advise patients to report severe or prolonged diarrhoea promptly
• In patients with prior CDI, prefer non-cephalosporin alternatives when possible

🧪 Antibiotic stewardship implication

The CDI risk from third-generation cephalosporins is a real stewardship concern. When narrower agents would work (nitrofurantoin or trimethoprim-sulfamethoxazole for uncomplicated cystitis; amoxicillin for pharyngitis without allergy), those are often preferred over cefixime for lower CDI risk. Cefixime should be reserved for indications where its specific spectrum or oral third-generation coverage is needed. This is a broader stewardship theme in antimicrobial prescribing.

🫀 Hepatic adverse effect spectrum

Asymptomatic LFT elevation

Mild transient rise in ALT, AST, alkaline phosphatase in 1 to 3 percent of patients. Usually resolves after course ends without intervention.

Cholestatic hepatitis

Rare. Presents with jaundice, dark urine, pruritus, right upper quadrant discomfort. Discontinue and evaluate.

Biliary sludge (particularly with ceftriaxone; less with cefixime)

Cephalosporins can concentrate in bile and produce biliary sludge. This is more of a concern with high-dose IV ceftriaxone than with oral cefixime, but has been reported.

Acute liver failure

Very rare with oral cefixime. If suspected, urgent hepatology consultation.

Hypersensitivity hepatitis

Part of severe hypersensitivity reactions (DRESS syndrome); very rare.

🔬 Biliary sludge context

Ceftriaxone can produce reversible biliary sludge or "pseudolithiasis" that appears as gallstones on ultrasound but resolves after drug discontinuation. This is because ceftriaxone is excreted in bile at very high concentrations. Cefixime shares partial biliary excretion but at lower concentrations, so the biliary sludge phenomenon is much less common. In patients with pre-existing gallstones or biliary dysfunction, this remains a consideration but is not a strong contraindication for cefixime.

✅ Monitoring and management approach

For short courses (7 to 14 days) in patients without liver disease, routine LFT monitoring is not required. For extended courses (typhoid 14 days, complicated infections), baseline and periodic LFT checks are prudent. Discontinue if ALT or AST rises above 3 times upper limit of normal, or if any clinical features of hepatitis develop. Full recovery typically occurs within weeks to months of discontinuation.

🩸 Haematologic adverse effects

Positive direct Coombs test

Cefixime can cause a positive direct antiglobulin test in a subset of patients. Usually clinically insignificant but can complicate blood typing and cross-matching. Discontinue if haemolytic anaemia develops.

Haemolytic anaemia

Rare drug-induced immune haemolytic anaemia. Symptoms include fatigue, jaundice, dark urine, splenomegaly. Requires immediate discontinuation and specialist evaluation.

Neutropenia

Rare, more common with prolonged courses. Usually reversible after stopping.

Thrombocytopenia

Rare. Bleeding or bruising warrants CBC evaluation.

Eosinophilia

More common than the above; may be an early marker of hypersensitivity reaction (particularly interstitial nephritis or DRESS).

Vitamin K deficiency bleeding

Rare consequence of prolonged gut flora disruption. More common in malnourished or long-course patients. Elevated INR without anticoagulant, easy bruising.

🧫 Renal adverse effects

Acute interstitial nephritis (AIN)

Hypersensitivity-mediated kidney injury. Classic presentation: fever, rash, eosinophilia plus acute kidney injury 1 to 3 weeks after starting. Rare but recognised beta-lactam reaction. Requires discontinuation and often corticosteroids.

Dose-related accumulation in CKD

Failing to adjust dose in CKD leads to elevated cefixime levels, increasing risk of neurotoxicity (seizures) and other adverse effects.

Prerenal effects from dehydration

Prolonged diarrhoea from cefixime can cause volume depletion and worsen kidney function in vulnerable patients.

Rare direct tubular toxicity

Less pronounced than aminoglycosides but has been described.

⚠️ Watch for these warning signs

• Unexplained fatigue or pallor (haemolytic anaemia)
• Jaundice or dark urine (haemolysis or hepatitis)
• Easy bruising or bleeding (thrombocytopenia or vitamin K deficiency)
• Reduced urine output or new peripheral oedema (kidney effects)
• Fever with rash and joint pain (interstitial nephritis or serum sickness-like)
• Sore throat or unexplained fever (neutropenia)
• Any of these warrant blood tests and possible cefixime discontinuation

🧪 Monitoring in extended treatment

For short outpatient courses (7 to 14 days), routine haematologic and renal monitoring beyond baseline is generally not needed. For extended courses (14-day typhoid), consider baseline and end-of-treatment CBC and renal function. In older adults or those with CKD, more frequent monitoring is prudent. For patients on long-term or repeat cephalosporin courses, periodic surveillance for cumulative effects becomes appropriate.

🧪 Resistance mechanisms

Extended-spectrum beta-lactamases (ESBL)

Plasmid-mediated enzymes (CTX-M dominant globally; TEM and SHV variants) that hydrolyse third-generation cephalosporins including cefixime. CTX-M-15 spread from India worldwide over the past two decades and now dominates community Enterobacteriaceae isolates in many regions.

AmpC beta-lactamases

Chromosomally encoded in some organisms (Enterobacter, Citrobacter, Serratia). Can be induced during treatment. Confer resistance to third-generation cephalosporins.

Carbapenemases

Confer resistance to carbapenems and typically to all third-generation cephalosporins. KPC, NDM, OXA-48, VIM types. Increasing globally.

Porin loss

Reduced outer membrane porin expression limits cefixime entry into Gram-negative cells. Often combined with ESBL production.

N. gonorrhoeae mosaic penA genes

Altered PBP2 reduces cefixime affinity. Emerged in Japan, spread globally. Underlies clinical cefixime treatment failures for gonorrhoea.

🔴 The ESBL empirical dilemma

In regions where community ESBL rates in E. coli exceed 15 to 20 percent, empirical cefixime for outpatient UTI risks treatment failure at a clinically meaningful rate. Nitrofurantoin retains excellent susceptibility even in ESBL-producing organisms; trimethoprim-sulfamethoxazole susceptibility depends on regional pattern. For patients with prior ESBL infection, recent hospitalisation, immunocompromise, or foreign travel to high-ESBL regions, cefixime empirically is not appropriate; culture-directed therapy or broader coverage is needed.

🧪 The CTX-M-15 pandemic

CTX-M-15 emerged in India in the late 1990s and has spread across the globe over the past two decades. It is now the dominant ESBL in community Enterobacteriaceae in most parts of the world. This spread has been driven by international travel, food trade, and the plasmid's efficient horizontal spread. Local surveillance data on ESBL rates should inform empirical antibiotic choice; cefixime is not appropriate empirical UTI treatment in high-ESBL regions.

✅ Cross-resistance and treatment options for ESBL infections

ESBL production confers resistance to cefixime, ceftriaxone, ceftazidime, and other third-generation cephalosporins. Fourth-generation cefepime may retain activity in some cases but is unreliable. Carbapenems (meropenem, ertapenem) remain the mainstay for serious ESBL infections. Newer beta-lactam/beta-lactamase inhibitor combinations (ceftazidime-avibactam, ceftolozane-tazobactam) address ESBL as well. Piperacillin-tazobactam is variable. For uncomplicated ESBL UTI, nitrofurantoin or fosfomycin can be effective outpatient options.

🛡️ Stewardship principles for cefixime

Narrower agent first when it fits

Amoxicillin for streptococcal pharyngitis; nitrofurantoin or trimethoprim-sulfamethoxazole for uncomplicated cystitis; cephalexin for MSSA skin infection. Reserve cefixime for its specific niches.

Culture-directed therapy where feasible

In non-emergent outpatient settings, waiting 24 to 48 hours for culture results and switching to narrower agent based on susceptibility is often possible. This reduces unnecessary broad-spectrum exposure.

Appropriate duration

Shorter courses are increasingly evidence-supported (5 to 7 days often adequate for cystitis; 7 days for uncomplicated pyelonephritis). Do not extend courses without indication.

Avoid antibiotics for viral URI

Most sinusitis, bronchitis, and pharyngitis are viral. Antibiotic prescription for these worsens the community CDI and resistance burden without patient benefit.

Track local resistance patterns

Local antibiograms guide empirical choice. In high-ESBL settings, cefixime empirical UTI treatment fails often enough that other agents are preferred.

✅ Legitimate cefixime uses (where cefixime genuinely fits)

• Uncomplicated UTI in low-ESBL settings when nitrofurantoin or trimethoprim-sulfamethoxazole is contraindicated
• UTI in pregnancy (Category B; safer than fluoroquinolones)
• Typhoid fever in endemic settings (susceptible strains)
• Paediatric otitis media penicillin allergy or amoxicillin failure
• Streptococcal pharyngitis in non-severe penicillin allergy
• Step-down from IV ceftriaxone for various indications
• Specific niche uses in specific patient populations

🔴 Situations where cefixime should NOT be used

• Uncomplicated cystitis where narrower agent works (nitrofurantoin, trimethoprim-sulfamethoxazole)
• Streptococcal pharyngitis without penicillin allergy (use penicillin or amoxicillin)
• Viral URI, viral bronchitis, viral pharyngitis (no antibiotic indicated)
• MSSA skin/soft tissue infection (use cephalexin or antistaphylococcal agent)
• Empirical gonorrhoea treatment (use ceftriaxone IM)
• Meningitis (poor CSF penetration)
• Pseudomonas infections
• Serious infection in patient with prior CDI (use narrower agent)

🧪 Regional stewardship context

The specific role of cefixime varies by region. In North America and Europe, stewardship programmes actively discourage third-generation cephalosporin overuse. In parts of South Asia and Africa, cefixime remains an important oral cephalosporin option where fluoroquinolone resistance is high and injectable ceftriaxone is impractical. Local practice patterns, resistance profiles, and healthcare infrastructure shape appropriate use. Stewardship programmes globally focus on matching antibiotic breadth to actual clinical need.

📦 Suspension reconstitution and use

• Reconstitute with water per manufacturer's marking on the bottle
• Shake vigorously after reconstitution to fully suspend
• Shake well before every dose as suspension can settle
• Use manufacturer-provided dosing device (syringe or cup) for accuracy — NOT household teaspoons
• Refrigeration improves taste and may improve palatability for reluctant paediatric patients
• Discard remaining suspension 14 days after reconstitution even if the course is not complete
• Do not freeze suspension

✅ Tablet storage rules

• Original blister or bottle for extended storage
• Cool, dry location (not bathroom cabinet)
• Keep out of reach of children
• Do not use tablets with damaged coating or altered appearance
• Discard past printed expiration date
• Travel-friendly at typical ambient temperatures

🧪 Paediatric practical tip

For a 10-day AOM course with suspension: reconstitute, refrigerate, shake before each dose. Cold suspension often tastes less objectionable to children than room-temperature suspension. If a child refuses despite palatable strawberry flavour, chewable tablets in the correct dose may be more acceptable for older children. Discuss adherence realistically with parents before prescribing multi-day courses.

⏰ Missed dose rules by regimen

Once daily 400 mg regimen

If under 12 hours late: take as soon as remembered. If over 12 hours late: skip and take next dose at usual time next day.

Twice daily 200 mg regimen

If under 6 hours late: take as soon as remembered. If over 6 hours late: skip and take next dose at usual time.

Multiple doses missed in a day

Resume regular schedule at next dose. Do not double up. Contact prescriber if serious infection course.

Typhoid 400 mg BID regimen

More attention to adherence given serious infection; contact prescriber for multiple missed doses.

🔴 Do not double-dose

Taking two doses close together does not improve outcome and increases GI upset risk. Continue with regular schedule after any missed dose.

💡 Adherence tips

• Anchor doses to routine activities (morning routine for OD; morning and evening for BID)
• Set phone alarms — particularly important for BID
• Pill organiser for adults; dose diary for paediatric suspension
• Take with or without food — simpler routine than tetracyclines
• Complete the full course even if symptoms improve early
• 10-day course for streptococcal pharyngitis: strict adherence required for rheumatic fever prevention
• For paediatric suspension: mark daily doses on the bottle or use tracking apps

🧪 If several doses missed in a short course

For a 7 to 14 day course, missing multiple doses risks sub-therapeutic tissue levels and treatment failure. Contact the prescriber — they may extend the course, restart, or reassess treatment approach. This is particularly important for pharyngitis courses (rheumatic fever risk with under-treatment), typhoid, and other serious infections.

✅ Advantages of cefixime in older adults

• Once-daily dosing supports adherence
• Take with or without food — no strict fasting rules
• Minimal drug interactions in polypharmacy compared with macrolides or fluoroquinolones
• No QT prolongation concerns
• No tendon or aortic risks like fluoroquinolones
• Good safety profile when renal function is properly assessed

🔴 Key concerns in older adults

• Renal function decline: even with normal creatinine, GFR often declines with age; cefixime accumulates
• C. difficile risk: significantly elevated in older adults; cephalosporin class is high-risk
• Concurrent PPI use: further increases CDI risk
• Warfarin monitoring: INR may rise; more frequent checks needed
• Community ESBL rise: empirical failure risk in high-ESBL regions
• Prior CDI history: consider narrower alternative if any

✅ Bottom line for older adults

Cefixime is a reasonable choice in older adults for its specific indications with proper renal dose adjustment. Its clean drug interaction profile makes it suitable for polypharmacy. However, the CDI risk associated with the cephalosporin class means that narrower alternatives (nitrofurantoin, trimethoprim-sulfamethoxazole for UTI; penicillin V for strep) should be preferred when they cover the target pathogen. In older adults with prior CDI, avoid cefixime when possible.

👶 Paediatric special populations

Neonates and infants under 6 months

Not FDA approved. Safety not established. Use IV cephalosporin (ceftriaxone or cefotaxime) in this age group if a third-generation cephalosporin is needed.

Neonatal jaundice

Ceftriaxone displaces bilirubin from albumin and worsens neonatal jaundice; cefixime shares this concern to a lesser degree. Avoid in neonates with hyperbilirubinaemia. Use different antibiotic class if possible.

Children with immune deficiency

Broader coverage needed for serious infection; oral cefixime as monotherapy usually inadequate. IV therapy with specialist input.

Children with recurrent AOM despite amoxicillin

Cefixime is a reasonable next step. Some children have H. influenzae-dominant otitis where cefixime coverage is better than amoxicillin.

Children with allergies

Serum sickness-like reactions to cephalosporins are more common in children than adults. Recognise and stop drug if febrile arthralgia-rash syndrome develops 1 to 3 weeks after starting.

Children with cystic fibrosis

Not for pulmonary exacerbation (no Pseudomonas coverage). Cefixime may be used for non-pulmonary infections.

Children in typhoid-endemic settings

Cefixime 20 mg/kg/day BID for 7 to 14 days is standard for uncomplicated typhoid in children. Check for XDR resistance in relevant regions.

⚠️ Serum sickness-like reaction in children

Serum sickness-like reaction (SSLR) is characterised by fever, arthralgia (particularly in large joints), and urticarial rash 1 to 3 weeks after starting a cephalosporin. It is more common in children than adults, and cefixime shares this risk with the class. Symptoms usually resolve within days of discontinuation. Antihistamines and short-course NSAIDs or steroids can help. Future cefixime use is generally avoided; other cephalosporins may be acceptable but require caution.

✅ Paediatric counselling essentials

• Explain the specific indication and expected response time
• Complete the full course even if child seems better
• Correct dose measurement with syringe or cup (not household spoons)
• Report new rash, fever, or joint pain promptly
• Report severe or prolonged diarrhoea (CDI concern)
• Refrigerate reconstituted suspension
• Follow up after treatment if symptoms persist
• Have information available on what to do if a dose is missed

⛔ Do not use cefixime

• Prior anaphylaxis to any cephalosporin or beta-lactam
• Prior SJS, TEN, DRESS from cephalosporins
• Prior severe cefixime reaction
• Anaphylactic penicillin allergy (avoid all beta-lactams)
• Neonates and infants under 6 months
• Meningitis or CNS infection (inadequate CSF penetration)
• Pseudomonas infections
• MRSA infections
• Enterococcal infections
• Documented ESBL infection with susceptibility to non-cephalosporin
• Empirical gonorrhoea treatment (use ceftriaxone IM)

🟡 Consider alternative

• Uncomplicated cystitis when nitrofurantoin or trimethoprim-sulfamethoxazole work (narrower spectrum preferred)
• Streptococcal pharyngitis without penicillin allergy (use penicillin V or amoxicillin)
• MSSA skin infection (use cephalexin instead of cefixime)
• Prior CDI history (avoid cephalosporins when possible)
• Immunocompromised patient with serious infection (IV therapy preferred)
• High-ESBL region empirical UTI treatment
• Severe allergy to cephalosporins even if non-life-threatening
• Renal dose adjustment challenging in specific clinical setting

✅ Where cefixime genuinely fits

Non-severe penicillin allergy with strep, sinusitis, or UTI where cephalosporin is appropriate; uncomplicated typhoid in endemic settings (susceptible strains); paediatric AOM after amoxicillin failure or in penicillin-allergic children; pregnancy UTI (Category B); step-down therapy after IV ceftriaxone; specific STI regimens where ceftriaxone is unavailable (higher-dose cefixime plus azithromycin).

🔄 Common alternatives

For uncomplicated cystitis: nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin. For pyelonephritis: ciprofloxacin or trimethoprim-sulfamethoxazole (or ceftriaxone IV loading dose then oral step-down). For strep pharyngitis: penicillin V or amoxicillin first-line. For AOM: high-dose amoxicillin or amoxicillin-clavulanate. For sinusitis: amoxicillin-clavulanate first-line. For MSSA skin: cephalexin. For typhoid: azithromycin (particularly for XDR regions), fluoroquinolones (susceptible), or carbapenems (severe/XDR). For gonorrhoea: ceftriaxone 500 mg IM.

🔭 Future outlook

Continued outpatient niche

Cefixime remains a useful oral third-generation cephalosporin for specific outpatient indications. Its role has narrowed but is not going away.

Gonorrhoea role continues to shrink

Rising N. gonorrhoeae resistance and ceftriaxone dose increases mean cefixime plays only a very narrow alternative role in STI treatment. Newer agents (gepotidacin, zoliflodacin) in development for gonorrhoea.

Typhoid role evolving with XDR spread

In XDR-typhoid regions, cefixime is not effective. Azithromycin, carbapenems, and typhoid conjugate vaccine expansion are the response. Cefixime remains useful in non-XDR regions.

Community ESBL rise limits UTI empirical use

Ongoing global rise in ESBL rates further limits empirical cefixime for community UTI. Local surveillance guides use.

Pediatric AOM continued role

Palatable suspension formulations and once-daily dosing keep cefixime relevant in paediatric practice for specific AOM scenarios and penicillin-allergic children.

Generic availability sustained

Multiple generic manufacturers globally ensure long-term availability at reasonable cost.

✅ Overall value

Cefixime (Suprax) represents a well-established oral third-generation cephalosporin with three decades of clinical experience. Its combination of oral bioavailability, once-daily dosing, and cephalosporin-class Gram-negative coverage fills specific niches in outpatient practice that few other agents cover. Its role has narrowed appropriately as gonorrhoea resistance emerged and ESBL spread limited UTI empirical use, but it remains valuable for penicillin-allergic patients with strep pharyngitis, paediatric AOM after amoxicillin failure, uncomplicated typhoid in endemic settings, and specific outpatient scenarios where its unique profile is genuinely needed.

⛔ Absolute contraindications

Prior anaphylaxis to cefixime or any cephalosporin

Lifetime avoidance.

Prior SJS, TEN, or DRESS from any cephalosporin

Lifetime class avoidance.

Anaphylactic penicillin allergy

Avoid all beta-lactams including cephalosporins until formal allergist evaluation.

Neonates and infants under 6 months

Safety not established. Not FDA approved in this age group.

Meningitis or CNS infection

CSF penetration inadequate. Use IV ceftriaxone or cefotaxime.

Pseudomonas infections

No activity. Use antipseudomonal agent.

MRSA infections

Not effective.

Non-bacterial infection (viral URI, viral bronchitis)

Antibiotic not indicated.

Empirical gonorrhoea treatment

Use ceftriaxone 500 mg IM.

🟡 Relative contraindications and cautions

Renal impairment

Dose reduction required at CrCl below 60 mL/min. See dedicated section.

Prior CDI

Prefer non-cephalosporin alternative when possible.

Concurrent warfarin

Monitor INR; expect modest elevation.

Community ESBL rise in region

Empirical use less reliable; consider culture-directed therapy.

Documented penicillin allergy without anaphylaxis

Cefixime usually acceptable but discuss and document rationale.

Live oral typhoid vaccine within 3 days

Space by 3 days minimum to avoid vaccine inactivation.

Pregnancy

Category B; acceptable for appropriate indications.

Lactation

Generally compatible with breastfeeding; watch infant.

Older adults

CDI risk, renal function assessment, PPI review.

📋 Populations requiring extra care

• Prior CDI or ongoing high antibiotic exposure
• Documented cephalosporin or penicillin allergy
• Renal impairment (dose adjustment)
• Older adults (CDI risk, renal function)
• Infants under 6 months (not approved)
• Neonates with hyperbilirubinaemia
• Immunocompromised patients (may need broader coverage)
• Regions with high community ESBL prevalence
• Regions with XDR-typhoid emergence
• Patients receiving live oral typhoid vaccine